This finding aligns with previous reports that also link low FTO levels to glioma malignancy (Chai et al., 2019; Tao et al., 2020; Zhang et al., 2022), solidifying its potential as a prognostic biomarker. The gene discussed is FTO; the disease is central nervous system cancer.